Medis
Martina Kaic has over 12 years of experience in regulatory affairs and pharmacovigilance. Martina has worked at Medis since 2016, initially as the Regulatory and Pharmacovigilance Manager and later as the Head of Regulatory Affairs for EU Countries. Martina also served as the Deputy EEA QPPV and the local QPPV in Croatia. Prior to that, they worked at Novo Nordisk as a Regulatory Affairs professional from 2014 to 2016. Before joining Novo Nordisk, they were a Regulatory & Pharmacovigilance Expert at Medis Adria d.o.o. from 2009 to 2014.
Martina Kaic commenced their education at V Gymnasium in 1990, where they studied until 1994. Martina then pursued their academic career at the Faculty of Pharmacy and Biochemistry from 1994 to 1999, focusing on the field of Pharmacy. No degree name was provided for their time at the Faculty of Pharmacy and Biochemistry.
This person is not in any offices
Medis
1 followers
For 34 years, we have been collaborating with global pharma and biotech partners to bring innovative therapies to patients in Central and Eastern Europe. Despite the region's challenging healthcare systems and complex yet promising markets, our team of 400 employees harnesses its expertise to ensure health equity in these underserved markets. Medis is a member of the World Orphan Drug Alliance (WODA) – a global alliance of full-service regional distributors for orphan and debilitating disease products. WODA covers 152 countries in the following regions: Central and Eastern Europe, Greater China, Israel, Greece, Malta, Cyprus, Latin America, the Middle East, North Africa & Turkey, Switzerland, Australia, New Zealand and South East Asia. Out-licensing: Become our commercialization partner and benefit from advanced, ready-to-launch consumer health products, which are already marketed in 20 countries and are further expanding. More information: www.medis.com/en/international-business/ Our business areas: • Therapeutics • Hospital Care • Consumer Health • Aesthetics Our value to partners: • Direct local presence in 18 CEE countries • Full commercialization • Single point of contact and delivery • Strategic and localized market access approach • Highest compliance standards • Financial and credit excellence Major Partners: • Therapeutics: Bial – Biogen – Besins – HRA Pharma – Mundipharma – Pierre Fabre – Santen – UCB • Hospital Care: Abbott – Aesculap – Asahi Medical – Biotest – B. Braun – Cytosorbents – Paion • Consumer Health: Pleuran – Ricerpharma – Karo Healthcare – Merz – Pohl Boskamp – UP – URGO • Aesthetics: Merz Aesthetics – Crown Aesthetics • Out-licensing partners: Ferrer – Pharmalink – Sarantis – Stada